Prohibiting retreatment with anti-PD-(L)1 agents decreased life-years (-6%), QALYs (-2%), deaths (-5%), the number of active treatments for metastatic disease (-10%), and the number of adverse events (-69%). The gene discussed is CD274; the disease is metastatic neoplasm.